The MET oncogene is known to sustain the Trousseau's syndrome in murine experimental models, featuring association of carcinogenesis with a blood procoagulant disorder. MET is frequently overexpressed in colorectal cancer, a tumor where venous thromboembolism (VTE) may occur in association with poor prognosis, but the biological and genetic factors that cause VTE are still obscure. The Investigators propose to study whether in patients harboring a surgically resectable colorectal cancer the MET oncogene is expressed and may be associated with a blood thrombophilic condition that favors the onset of VTE. These data would have two main implications: (i) for the first time, a direct genetic link between the MET oncogene and a procoagulant disorder would be demonstrated in humans; (ii) the procoagulant alterations would have diagnostic/prognostic significance for the identification of patients at risk for poor outcome, and implementation of appropriate therapeutic protocols.
Study Type
OBSERVATIONAL
Enrollment
60
Fondazione del Piemonte per l'Oncologia
Candiolo, TO, Italy
Scoring MET expression in colorectal tissue sections by immunohistochemical analysis
Time frame: After surgical resection of the tumor, approximately 3-5 days after enrollement
Scoring the expression of Plasminogen Activator Inhibitor -1 in colorectal cancer tissue sections by Immunohistochemical analysis
Time frame: After surgical resection of the tumor, approximately 3-5 days after enrollement
Scoring the expression of COX-2 in colorectal cancer tissue sections by Immunohistochemical analysis
Time frame: After surgical resection of the tumor, approximately 3-5 days after enrollement
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.